IFNL4 ss469415590 Variant Is Associated with Treatment Response in Japanese HCV Genotype 1 Infected Individuals Treated with IFN-Including Regimens
Joint Authors
Imazeki, Fumio
Yokosuka, Osamu
Yasui, Shin
Nakamura, Masato
Chiba, Tetsuhiro
Arai, Makoto
Wu, Shuang
Jiang, Xia
Sasaki, Reina
Haga, Yuki
Ooka, Yoshihiko
Mikami, Shigeru
Nakamoto, Shingo
Miyamura, Tatsuo
Kanda, Tatsuo
Source
International Journal of Hepatology
Issue
Vol. 2014, Issue 2014 (31 Dec. 2014), pp.1-6, 6 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2014-12-08
Country of Publication
Egypt
No. of Pages
6
Main Subjects
Abstract EN
Aim.
Eradication of hepatitis C virus (HCV) is still challenging even if interferon- (IFN-) free regimens with direct-acting antiviral agents (DAAs) for HCV-infected individuals are available in clinical practice.
IFNL4 is a newly described protein, associated with human antiviral defenses.
We investigated whether IFNL4 ss469415590 variant has an effect on the prediction of treatment response in HCV-infected patients treated with IFN-including regimens.
Patients and Methods.
In all, 185 patients infected with HCV genotype 1 treated with peg-IFN plus ribavirin, with or without telaprevir, were genotyped for IFNL4 ss469415590.
We retrospectively investigated whether the role of IFNL4 ss469415590 variant and other factors could predict sustained virological response (SVR) in Japanese patients infected with HCV genotype 1.
Results.
There were 65.7%, 31.5%, and 2.8% patients in the IFNL4 ss469415590 TT/TT, TT/-G, and -G/-G groups, respectively.
SVR rates were 82.1% or 49.3% in patients treated with peg-IFN plus ribavirin with or without telaprevir, respectively.
IFNL4 ss469415590 variant and HCV viral loads or IFNL4 ss469415590 variant and early virological response were better predictors of SVR in patients treated with peg-IFN plus ribavirin with or without telaprevir, respectively.
Conclusion.
In the era of DAAs, measurement of IFNL4 ss469415590 variant could help the prediction of SVR in Japanese HCV genotype 1 infected individuals treated with IFN-including regimens.
American Psychological Association (APA)
Miyamura, Tatsuo& Kanda, Tatsuo& Nakamoto, Shingo& Arai, Makoto& Nakamura, Masato& Wu, Shuang…[et al.]. 2014. IFNL4 ss469415590 Variant Is Associated with Treatment Response in Japanese HCV Genotype 1 Infected Individuals Treated with IFN-Including Regimens. International Journal of Hepatology،Vol. 2014, no. 2014, pp.1-6.
https://search.emarefa.net/detail/BIM-1036709
Modern Language Association (MLA)
Miyamura, Tatsuo…[et al.]. IFNL4 ss469415590 Variant Is Associated with Treatment Response in Japanese HCV Genotype 1 Infected Individuals Treated with IFN-Including Regimens. International Journal of Hepatology No. 2014 (2014), pp.1-6.
https://search.emarefa.net/detail/BIM-1036709
American Medical Association (AMA)
Miyamura, Tatsuo& Kanda, Tatsuo& Nakamoto, Shingo& Arai, Makoto& Nakamura, Masato& Wu, Shuang…[et al.]. IFNL4 ss469415590 Variant Is Associated with Treatment Response in Japanese HCV Genotype 1 Infected Individuals Treated with IFN-Including Regimens. International Journal of Hepatology. 2014. Vol. 2014, no. 2014, pp.1-6.
https://search.emarefa.net/detail/BIM-1036709
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1036709